MX2023015238A - Formulaciones de proteinas quimericas del factor viii y usos de las mismas. - Google Patents
Formulaciones de proteinas quimericas del factor viii y usos de las mismas.Info
- Publication number
- MX2023015238A MX2023015238A MX2023015238A MX2023015238A MX2023015238A MX 2023015238 A MX2023015238 A MX 2023015238A MX 2023015238 A MX2023015238 A MX 2023015238A MX 2023015238 A MX2023015238 A MX 2023015238A MX 2023015238 A MX2023015238 A MX 2023015238A
- Authority
- MX
- Mexico
- Prior art keywords
- factor viii
- formulations
- chimeric proteins
- viii chimeric
- polypeptide
- Prior art date
Links
- 229960000301 factor viii Drugs 0.000 title abstract 3
- 102000037865 fusion proteins Human genes 0.000 title abstract 2
- 108020001507 fusion proteins Proteins 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 108010054218 Factor VIII Proteins 0.000 abstract 2
- 102000001690 Factor VIII Human genes 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 108010047303 von Willebrand Factor Proteins 0.000 abstract 2
- 102100036537 von Willebrand factor Human genes 0.000 abstract 2
- 229960001134 von willebrand factor Drugs 0.000 abstract 2
- 102100026735 Coagulation factor VIII Human genes 0.000 abstract 1
- 201000003542 Factor VIII deficiency Diseases 0.000 abstract 1
- 208000009292 Hemophilia A Diseases 0.000 abstract 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163214246P | 2021-06-23 | 2021-06-23 | |
| US202163214245P | 2021-06-23 | 2021-06-23 | |
| US202163214752P | 2021-06-24 | 2021-06-24 | |
| US202163231909P | 2021-08-11 | 2021-08-11 | |
| PCT/US2022/034747 WO2022271962A1 (en) | 2021-06-23 | 2022-06-23 | Formulations of factor viii chimeric proteins and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023015238A true MX2023015238A (es) | 2024-03-08 |
Family
ID=82656587
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023015238A MX2023015238A (es) | 2021-06-23 | 2022-06-23 | Formulaciones de proteinas quimericas del factor viii y usos de las mismas. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240287158A1 (enExample) |
| EP (1) | EP4358938A1 (enExample) |
| JP (1) | JP2024522855A (enExample) |
| KR (1) | KR20240024949A (enExample) |
| AU (1) | AU2022298798A1 (enExample) |
| BR (1) | BR112023026782A2 (enExample) |
| CA (1) | CA3220564A1 (enExample) |
| CO (1) | CO2023017358A2 (enExample) |
| IL (1) | IL309309A (enExample) |
| MX (1) | MX2023015238A (enExample) |
| TW (1) | TW202317178A (enExample) |
| WO (1) | WO2022271962A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201691111A1 (ru) | 2014-01-10 | 2017-01-30 | Байоджен Ма Инк. | Химерные белки фактора viii и их применение |
| EP4489771A2 (en) * | 2022-03-08 | 2025-01-15 | Bioverativ Therapeutics Inc. | Methods of treating hemophilia a |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE198277T1 (de) * | 1992-10-02 | 2001-01-15 | Genetics Inst | Zusammensetzung, welche den koagulationsfaktor viii beinhaltet; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator |
| EP2385825B1 (en) * | 2008-11-07 | 2018-10-10 | University of Connecticut | Factor viii formulations |
| ES2770501T3 (es) | 2012-07-11 | 2020-07-01 | Bioverativ Therapeutics Inc | Complejo del factor VIII con XTEN y proteína del factor de Von Willebrand y sus usos |
| EA201691111A1 (ru) | 2014-01-10 | 2017-01-30 | Байоджен Ма Инк. | Химерные белки фактора viii и их применение |
| KR102914074B1 (ko) | 2018-05-18 | 2026-01-16 | 바이오버라티브 테라퓨틱스 인크. | A형 혈우병의 치료 방법 |
| AU2020298233A1 (en) * | 2019-06-19 | 2022-01-20 | Bioverativ Therapeutics Inc. | Recombinant factor VIII-Fc for treating hemophilia and low bone mineral density |
| WO2021032646A1 (en) * | 2019-08-16 | 2021-02-25 | Octapharma Ag | Stabilizing buffer for factor viii and vwf |
| EP4489771A2 (en) * | 2022-03-08 | 2025-01-15 | Bioverativ Therapeutics Inc. | Methods of treating hemophilia a |
-
2022
- 2022-06-23 TW TW111123492A patent/TW202317178A/zh unknown
- 2022-06-23 BR BR112023026782A patent/BR112023026782A2/pt unknown
- 2022-06-23 EP EP22744880.0A patent/EP4358938A1/en active Pending
- 2022-06-23 CA CA3220564A patent/CA3220564A1/en active Pending
- 2022-06-23 KR KR1020247002191A patent/KR20240024949A/ko active Pending
- 2022-06-23 WO PCT/US2022/034747 patent/WO2022271962A1/en not_active Ceased
- 2022-06-23 JP JP2023579138A patent/JP2024522855A/ja active Pending
- 2022-06-23 IL IL309309A patent/IL309309A/en unknown
- 2022-06-23 MX MX2023015238A patent/MX2023015238A/es unknown
- 2022-06-23 AU AU2022298798A patent/AU2022298798A1/en active Pending
- 2022-06-23 US US18/572,006 patent/US20240287158A1/en active Pending
-
2023
- 2023-12-14 CO CONC2023/0017358A patent/CO2023017358A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20240287158A1 (en) | 2024-08-29 |
| CA3220564A1 (en) | 2022-12-29 |
| TW202317178A (zh) | 2023-05-01 |
| CO2023017358A2 (es) | 2024-01-15 |
| IL309309A (en) | 2024-02-01 |
| EP4358938A1 (en) | 2024-05-01 |
| JP2024522855A (ja) | 2024-06-21 |
| KR20240024949A (ko) | 2024-02-26 |
| BR112023026782A2 (pt) | 2024-03-12 |
| AU2022298798A1 (en) | 2024-02-08 |
| WO2022271962A1 (en) | 2022-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024015540A (es) | Polipeptidos quimericos para usarse en el tratamiento de la hemofilia a | |
| HRP20220960T1 (hr) | Kimerni proteini faktora viii i njihova upotreba | |
| MX9305729A (es) | Formulas de proteinas de liberacion sostenida. | |
| GB2467700A (en) | Modified recombinant Factor VIII and von Willebrand Factor and methods of use | |
| CO2023017358A2 (es) | Formulaciones de proteínas quiméricas del factor viii y usos de las mismas | |
| DE60125381D1 (de) | Zusammensetzungen und verfahren mit analogen von g-csf | |
| WO2019191633A3 (en) | Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof | |
| ATE549028T1 (de) | Stabile analoga von glp-1 | |
| Gangadharan et al. | The C1 and C2 domains of blood coagulation factor VIII mediate its endocytosis by dendritic cells | |
| DE69727149D1 (de) | Varianten des vaskulären endothelzellwachsumsfaktors mit antagonistischer wirkung | |
| ATE442373T1 (de) | Nukleotid- und proteinsequenzen von delta-genen von vertebraten und darauf basierende methoden | |
| DK0672138T3 (da) | Kimære prokoagulante proteiner | |
| US10251940B2 (en) | Preparation comprising factor VIII and Von Willebrand factor peptides | |
| DE69713112D1 (de) | Zusammensetzungen und methoden zur behandlung von infektionen unter verwendung von indolicidin-analogen | |
| ATE466085T1 (de) | Protease-resistente modifizierte interferon alpha polypeptide | |
| DE60232577D1 (de) | Oligomerische komplexe von chimären proteinen mit verbessertem immunogenen potential | |
| ATE350049T1 (de) | Zusammensetzungen und verfahren zur behinderung der vervielfältigung von hiv-1 | |
| MX2023001262A (es) | Polipéptidos inhibidores del ligando 1 de muerte programada que prolongan la vida media del suero. | |
| ES2054365T3 (es) | Inhibicion de la via de la regla del n final en celulas vivas. | |
| MX2024004494A (es) | Formulaciones de proteinas quimericas de factor viii y usos de las mismas. | |
| MX2020013296A (es) | Composiciones que contienen inhibidor de proteasa recombinante, metodos para producir las mismas y usos de las mismas. | |
| CO2023000048A2 (es) | Conjugados de citoquina | |
| WO2023023588A3 (en) | Methods and compositions of inhibiting asprosin mediated orexigenesis and/or glucogenesis | |
| ATE316101T1 (de) | Thrombinspaltbare faktor-x-analoga | |
| ATE10364T1 (de) | Retro-inverso analoga von c-terminalen pentaund hexapeptiden der verbindung p. |